

Esbriet[®] (pirfenidone) – First-time generic

- On January 10, 2023, Amneal, Cipla, [Laurus](#) and Sandoz launched [AB-rated](#) generic versions of Genentech's [Esbriet \(pirfenidone\)](#) capsule.
 - [Accord](#) and [ScieGen](#) received FDA approval of AB-rated generic versions of Esbriet capsule on January 20, 2022 and August 1, 2022, respectively. Launch plans are pending.
- Esbriet is approved for the treatment of idiopathic pulmonary fibrosis.
- Pirfenidone is also available generically as [tablets](#) and carries the same indication as the capsule.